TMDX - Close to all time highs
18% off all time highs.
Held its EP gap from 7/11 on Highest Volume Ever.
A couple days to tighten here would be ideal for a low risk entry close to the 10 EMA.
−0.77USD
−25.03 MUSD
241.62 MUSD
31.48 M
About TransMedics Group, Inc.
Sector
Industry
CEO
Waleed H. Hassanein
Website
Headquarters
Andover
Employees (FY)
584
Founded
1998
FIGI
BBG00NZ6J685
TransMedics Group, Inc. operates as a commercial stage medical technology company. The firm engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in August 1998 and is headquartered in Andover, MA.
TransMedics Group, Inc. (TMDX:NASDAQ): Strong Q2 PerformanceTransMedics Group, Inc.: Strong Q2 Performance and Ambitious Expansion Plans
Exceptional Q2 Performance: TransMedics Group's Remarkable Growth: Achieving Record Revenues and Unprecedented Second-Quarter Turnover
TransMedics Group, Inc. has demonstrated remarkable growth in its Q2 results, showcasi
TMDX - Watch for $90.15Key level at $90.15, passing that area would clear any remaining overhead resistance and should set this up to run, tremendous sales numbers.
$TMDX using some imaginationusing some imagination on $TMDX (orange bars).
Company not making money yet but that sales growth is behind this insane relative strength.
For months while the market is in a bear, this stock is in its own bull cycle.
RS 99 and almost 90 degree up.
One to keep an eye on.
TMDX -- Long--Double bottom is form for a base/support
--holding on the long bottom trend support
--Risk: 14 days before ER
--Could hit near target before ER
--Would close position before ER in this market condition
--See chart
--Avoid choppy price action
TransMedics Announces Positive Top Line Results From the U.S. RaTMDX: TransMedics Group, Inc.
2021-11-04 07:00:00
TransMedics Announces Positive Top Line Results From the U.S. Randomized OCS DCD Heart Trial
TMDX - Quick lookBull and Bear case laid out. I may do an explanation later but too lazy right now.
Watch ~38 for a pivot.
good chance we bounce herewe have bounced off this support plenty of times in the past, great risk reward if we enter long with tight stop, long 29 stop loss 25.5 price target 38-45! goodluck :) please dont forget to like and follow if you like my ideas!
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of TMDX is 86.51 USD — it has increased by 2.79% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange TransMedics Group, Inc. stocks are traded under the ticker TMDX.
TransMedics Group, Inc. is going to release the next earnings report on Apr 30, 2024. Keep track of upcoming events with our Earnings Calendar.
TMDX stock is 4.32% volatile and has beta coefficient of 2.21. Check out the list of the most volatile stocks — is TransMedics Group, Inc. there?
One year price forecast for TransMedics Group, Inc. has a max estimate of 105.00 USD and a min estimate of 95.00 USD.
TMDX earnings for the last quarter are −0.78 USD per share, whereas the estimation was −0.16 USD resulting in a −380.99% surprise. The estimated earnings for the next quarter are −0.07 USD per share. See more details about TransMedics Group, Inc. earnings.
TransMedics Group, Inc. revenue for the last quarter amounts to 66.40 M USD despite the estimated figure of 49.19 M USD. In the next quarter revenue is expected to reach 68.49 M USD.
Yes, you can track TransMedics Group, Inc. financials in yearly and quarterly reports right on TradingView.
TMDX stock has fallen by 6.24% compared to the previous week, the month change is a 18.33% rise, over the last year TransMedics Group, Inc. has showed a 7.13% increase.
TMDX net income for the last quarter is 4.03 M USD, while the quarter before that showed −25.42 M USD of net income which accounts for 115.86% change. Track more TransMedics Group, Inc. financial stats to get the full picture.
Today TransMedics Group, Inc. has the market capitalization of 2.75 B, it has increased by 23.84% over the last week.
No, TMDX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, TMDX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade TransMedics Group, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 23, 2024, the company has 584.00 employees. See our rating of the largest employees — is TransMedics Group, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So TransMedics Group, Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating TransMedics Group, Inc. stock shows the buy signal. See more of TransMedics Group, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on TransMedics Group, Inc. future price: according to them, TMDX price has a max estimate of 105.00 USD and a min estimate of 95.00 USD. Read a more detailed TransMedics Group, Inc. forecast: see what analysts think of TransMedics Group, Inc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. TransMedics Group, Inc. EBITDA is 7.19 M USD, and current EBITDA margin is 3.63%. See more stats in TransMedics Group, Inc. financial statements.